Platelet-activating factor (PAF): A review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 2, Issue 1, 2008, Pages 72-76

  Kasperska Zajac, Alicja ^a,b   Brzoza, Zenon ^a   Rogala, Barbara ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Clinical Department of Internal Diseases Allergology and Clinical Immunology   (Poland)

Author keywords

Asthma; Platelet activating factor

Indexed keywords

1 ACETYL 4 (8 CHLORO 5,6 DIHYDRO 11H BENZO[5,6]CYCLOHEPTA[1,2 B]PYRIDIN 11 YLIDENE)PIPERIDINE; 1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APAFANT; FOROPAFANT; GINKGOLIDE B; IMIDAZOPYRIDINE DERIVATIVE; ISRAPAFANT; MODIPAFANT; PLACEBO; RECOMBINANT ENZYME; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; DRUG TARGETING; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; MONOTHERAPY; NONHUMAN; PATENT; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; DRUG DELIVERY SYSTEMS; HUMANS; PATENTS AS TOPIC; PLATELET ACTIVATING FACTOR; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, G-PROTEIN-COUPLED; UNITED STATES;

EID: 42149083258     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221308783399306     Document Type: Review

References (62)

1. Denjean A, Arnoux B, Benveniste J, Lockhart A, Masse R. Bronchoconstriction induced by intratracheal administration of platelet-activating factor (PAF-acether) in baboons. Agents Actions 1981; 11(6-7): 567-568.
2. Basran GS, Page CP, Paul W, Morley J. Platelet-activating factor: a possible mediator of the dual response to allergen? Clin Allergy 1984; 14(1): 75-79.
3. Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma: an update. Pharmacol Rev 1998; 50(4): 515-596.
4. Huang YH, Schafer-Elinder L, Owman H, Lorentzen JC, Ronnelid J, Frostegard J. Induction of IL-4 by platelet-activating factor. Clin Exp Immunol 1996; 106(1): 143-148.
5. Smith LJ. The role of platelet-activating factor in asthma. Am Rev Respir Dis 1991; 143(5 Pt2): S100-102.
6. Spina D, Coyle AJ, Page CP. The role of platelet activating factor in allergic inflammation. Pulm Pharmacol 1989; 2(1): 13-19.
7. Hwang SB. Specific receptors of platelet-activating factor, receptor heterogeneity and signal transduction mechanisms. J Lipid Mediat 1990; 2(3-4): 123-158.
8. Simon HU, Tsao PW, Siminovitch KA, Mills GB, Blaser K. Functional platelet-activating factor receptors are expressed by monocytes and granulocytes but not by resting or activated T and B lymphocytes from normal individuals or patients With asthma. J Immunol 1994; 153(1): 364-377.
9. Ishii S, Nagase T, Shindou H, Takizawa H, Ouchi Y, Shimizu T. Platelet-activating factor receptor develops airway hyperresponsiveness independently of airway inflammation in a murine asthma model. J Immunol 2004; 172(11): 7095-7102.
10. Taylor IK, Ward PS, Taylor GW, Dollery CT, Fuller RW. Inhaled PAF stimulates leukotriene and thromboxane A2 production in humans. J Appl Physiol 1901; 71(4): 1396-1402.
11. Fujiu T, Kato M, Kimura H, et al. Cellular adhesion is required for effector functions of human eosinophils via G-protein coupled receptors. Ann Allergy Asthma Immunol 2002; 89(1): 90-98.
12. Shindo K, Koide K, Hirai Y, Sumitomo M, Fukumura M. Priming effect of platelet activating factor on leukotriene C4 from stimulated eosinophils of asthmatic patiens. Thorax 1996; 51(2): 156-158.
13. Kroegel C, Matthys H. Platelet-activating factor-induced human eosinophil activation. Generation and release of cyclo-oxygenase metabolites in human blood eosinophils from asthmatics. Immunology 1993; 78(2): 279-285.
14. Casale TB, Erger RA, Little MM. Platelet-activating factor-induced human eosinophil transendothelial migration: evidence for a dynamic role of the endothelium. Am J Respir Cell Mol Biol 1993; 8(1): 77-82.
15. Wardlaw AJ, Moqbel R, Cromwell O, Kay AB. Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest 1986; 78(6): 1701-1706.
16. McFadden RG, Bishop MA, Caveney AN, Fraher LJ. Effect of platelet activating factor (PAF) on the migration of human lymphocytes. Thorax 1995; 50(3):265-269.
17. Thivierge M, Rola-Pleszczynski M. Platelet-activating factor enhances interleukin-6 production by alveolar macrophages. J Allergy Clin Immunol 1992; 90(5): 796-802.
18. Columbo M, Horowitz EM, Kagey-Sobotka A, Lichtenstein LM. Histamine release from human basophils induced by platelet activating factor: the role of extracellular calcium, interleukin-3, and granulocyte-macrophage colony-stimulating factor. J Allergy Clin Immunol 1995; 95(2): 565-573.
19. Nilsson G, Metcalfe DD, Taub DD. Demonstration that platelet-activating factor is capable of activating mast cells and inducing a chemotactic response. Immunology 2000; 99(2): 314-319.
20. Stewart AG, Phillips WA. Intracellular platelet-activating factor regulates eicosanoid generation in guinea-pig resident peritoneal macrophages. BT J Pharmacol 1989; 98(1): 141-148.
21. Hsieh KH, Ng CK. Increased plasma platelet-activating factor in children with acute asthmatic attacks and decreased in vivo and in vitro production of platelet-activating factor after immunotherapy. J Allergy Clin Immunol 1993; 91(2): 650-657.
22. Kurosawa M, Yamashita T, Kurimoto F. Increased levels of blood platelet-activating factor in bronchial asthmatic patients with active symptoms. Allergy 1994; 49(1): 60-63.
23. Chan-Yeung M, Lam S, Chan H, Tse KS, Salari H. The release of platelet-activating factor into plasma during allergen-induced bronchoconstriction. J Allergy Clin Inummol 1991; 87(3): 667-673.
24. Cuss FM, Dixon CM, Barnes PJ. Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man. Lancet 1986; 26:2(8500) 189-192.
25. Steiger J, Bray MA, Subramanian N. Platelet activating factor (PAF) is a potent stimulator of porcine tracheal fluid secretion in vitro. Eur J Pharmacol 1987; 142(3): 367-372
26. Chung KF, Cuss FM, Barnes PJ. Platelet activating factor: effects on bronchomotor tone and bronchial responsiveness in human beings. Allergy Proc 1989; 10(5): 333-337.
27. Louis RE, Radermecker MF. Acute bronchial obstruction following inhalation of PAF in asthmatic and normal subjects: comparison with methacholine. Eur Respir J 1996; 9(7): 1414-1420.
28. Adamus WS, Heuer HO, Meade CJ, Schilling JC. Inhibitory effects of the new PAF acether antagonist WEB-2086 on pharmacologic changes induced by PAF inhalation in human beings. Clin Pharmacol Ther 1990; 47(4): 456-462.
29. Hsieh KH. Effects of PAF antagonist, BN52021, on the PAF-methacholine, and allergen-induced bronchoconstriction in asthmatic children. Chest 1991; 99(4): 877-882.
30. Wardlaw AJ, Chung KF, Moqbel R, et al. Effects of inhaled PAF in humans on circulating and bronchoalveolar lavage fluid neutrophils. Relationship to bronchoconstriction and changes in airway responsiveness. Am Rev Respir Dis 1990; 141(2): 386-392.
31. Felez MA, Roca J, Barbera JA, et al. Inhaled platelet-activating factor worsens gas exchange in mild asthma. Am J Respir Crit Care Med 1994; 150(2):369-373.
32. Diaz O, Barbera JA, Marrades R, Chung KF, Roca J, Rodriguez-Roisin R. Inhibition of PAF-induced gas exchange defects by beta-adrenergic agonists in mild asthma is not due to bronchodilation. Am J Respir Crit Care Med 1997; 156(1): 17-22.
33. Gomez FP, Roca J, Barbera JA, Chung KF, Peinado VI, Rodriguez-Roisin R. Effect of a platelet-activating factor (PAF) antagonist, SR 27417A, on PAF-induced gas exchange abnormalities in mild asthma. Eur Respir J 1998; 11(4): 835-839.
34. Rodriguez-Roisin R, Felez MA, Chung KF, et al. Platelet-activating factor causes ventilation-perfusion mismatch in humans. J Clin Invest 1994; 93(1): 188-194.
35. Gomez FP, Iglesia R, Roca J, Barbera JA, Chung KF, Rodriguez-Roisin R. The effects of 5-lipoxygenase inhibition by zileuton on platelet-activating-factor-induced pulmonary abnormalities in mild asthma. Am J Respir Crit Care Med 1998; 157(5 Pt 1): 1559-1564.
36. Spencer DA, Evans J M, Green SE, Piper PJ, Costello JF. Participation of the cysteinyl leukotrienes in the acute bronchoconstriction response to inhaled platelet activating factor in man. Thorax 1991; 46(6): 441-445.
37. Kidney JC, Ridge SM, Chung KF, Barnes PJ. Inhibition of platelet-activating factor-induced bronchoconstriction by the leukotriene D4 receptor antagonist ICI 204,219. Am Rev Respir Dis 1993; 147(1): 215-217.
38. Sato T, Bewtra AK, Hopp RJ, Nair N, Townley RG. Alpha- and beta-adrenergic-receptor systems in bronchial asthma and in subjects without asthma reduced mononuclear cell beta-receptors in bronchial asthma. J Allergy Clin Immunol 1990; 86(6 PtI): 839-850.
39. Karasawa K, Harada A, Satoh N, Inoue K, Setaka M. Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res 2003; 42(2): 93-114.
40. Tjoelker LW, Stafforini DM. Platelet-activating factor acetyl hydrolases in health and disease. Biochim Biophys Acta 2000, 1488(1-2): 102-123.
41. Miwa M, Miyake T, Yamanaka T, et al. Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Invest 1988; 82(6): 1083-1991.
42. Stafforini DM, Numao T, Tsodikov A, et al. Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma. J Clin Invest 1999; 103(107): 989-997.
43. Satoh N, Asano K, Naoki K, et al. Plasma platelet-activating factor acetylhydrolase deficiency in Japanese patients with asthma. Am J Respir Crit Care Med 1999; 159(3): 974-79.
44. Triggiani M, De Marino V, Sofia M, et al. Characterization of platelet-activating factor acetylhydrolase in human bronchoalveolar lavage. Am J Respir Crit Care Med 1997; 156(1): 94-100.
45. Hozawa S, Haruta Y, Ishioka S, Yamakido M. Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. Am J Respir Crit Care Med 1995; 152(4 Pt 1): 1198-202.
46. Kuitert LM, Angus RM, Barnes NC, et al. Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma. Am J Respir Crit Care Med 1995; 151(5): 1331-1335.
47. Kuitert LM, Hui KP, Uthayarkumar S, et al. Effect of the platelet-activating factor antagonist UK-74,505 on the early and late response to allergen. Am Rev Respir Dis 1993; 147(1): 82-86.
48. Freitag A, Watson RM, Matsos G, Eastwood C, O'Byrne PM. Effect of a platelet activating factor antagonist, WEB 2086, on allergen induced asthmatic responses. Thorax 1993; 48(6): 594-598.
49. Spence DP, Johnston SL, Calverley PM, et al. The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma. Am J Respir Crit Care Med 1994; 149(5): 1142-1148.
50. Evans DJ, Barnes PJ, Cluzel M, O'Connor BJ. Effects of a potent platelet-activating factor antagonist, SR27417A, on allergen-induced asthmatic responses. Am J Respir Crit Care Med 1997;156(1): 11-16.
51. Gomez FP, Marrades RM, Iglesia R, et al. Gas exchange response to a PAF receptor antagonist, SR 27417A, in acute asthma: a pilot study. Eur Respir J 1999; 14(3): 622-626.
52. Henderson WR Jr, Lu J, Poole KM, Dietsch GN, Chi EY. Recombinant human platelet-activating factor-acetylhydrolase inhibits airway inflammation and hyperreactivity in mouse asthma model. J Immunol 2000; 164(6): 3360-3367.
53. Tjoelker LW, Wilder C, Eberhardt C, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995; 374(6522): 549-553.
54. Henig NR, Aitken ML, Liu MC, Yu AS, Henderson WR Jr. Effect of recombinant-human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses. Am J Respir Crit Care Med 2000; 162(2 Pt 1): 523-27.
55. Billah MM, Chapman RW, Watnick AS, Egan RW, Siegel MI, Kreutner W. Sch 37370: a new drug combining antagonism of platelet-activating factor (PAF) with antagonism of histamine. Agents Actions Suppl 1991; 34: 313-321.
56. Rigat, B., Reynaud, D., Mahuran, D.: US20026423680 (2002).
57. Cai, X., Hwang, S.B., Killian, D., Shen, T.Y., Hussoin, S.: US20016294574 (2001).
58. Caii, X., Grewal, G., Hussoin, S., Fura, A., Scannell, R., Biftu, T.: US20016201016 (2001).
59. Cai, X., Hussoin, S., Hwang, S.B., Killian, D., Shen, T.Y.: US5856323 (1999).
60. Ayscough, A. P., Blackwell, C. M., Launchbury, S., Whittaker, M.: US5866588 (1999).
61. Miller, A., Bowles, S. A., Ayscough, A. P., Whittaker, M.: US5753671 ( 1998).
62. Billah MM, Gilchrest HG, Eckel SP, et al. Differential plasma duration of antiplatelet-activating factor and antihistamine activities of oral Sch 37370 in hamans. Clin Pharmacol Ther 1992; 52(2): 151-59.